News & Updates

Among patients who successfully recover from the coronavirus disease 2019 (COVID-19), nearly half continue to experience persistent symptoms a month after recovery, reports a recent Japan study.

Treatment with remdesivir in patients hospitalized for COVID-19 does not appear to confer increased risks of acute kidney and liver injury, with a recent study showing that these risks are already elevated even before exposure to treatment and there is no further increase following remdesivir initiation.

Early administration (ie, within 5 days after symptom onset) of the oral, small-molecule antiviral prodrug molnupiravir slashed the risk of hospitalization or death in at-risk, unvaccinated, nonhospitalized adults with mild-to-moderate COVID-19, findings from the phase III component of the phase II/III MOVe-OUT trial have shown.

Declaring a state of emergency to curb the spread of the coronavirus disease 2019 (COVID-19) correlates with an increase in white coat hypertension, reports a recent Japan study.

Children with multisystem inflammatory syndrome in children (MIS-C) show significantly higher prevalence of cardiac complications, elevated markers of inflammation and cardiac damage, thrombocytopenia, and lymphopenia than do those with COVID-19, Kawasaki disease (KD), and toxic shock syndrome (TSS), reports a study.

Using C-reactive protein (CRP) levels as indicators for early treatment with tocilizumab and dexamethasone can help reduce mortality in hospitalized patients with the coronavirus disease 2019 (COVID-19), a recent study has found.

Coronavirus disease 2019 (COVID-19) patients treated with remdesivir appear to be at a higher likelihood of having elevated pancreatic enzyme levels, a recent Japan study has found.